TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00060632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Study: NCT03888651

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT00060632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Study: NCT03071887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program (3RP)
Description: The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
Study: NCT03176927

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetogastrogram
Study: NCT03762031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 30mg
Description: single dose given via a 15 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 60mg
Description: single dose given via a 15 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 90mg
Description: single dose given via a 15 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 120mg
Description: single dose given via a 15 minute intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of normal saline given via a 15 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 75mg
Description: single dose given via a 15 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 105mg
Description: single dose given via a 15 minute intravenous infusion
Study: NCT02254473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wedge Insert

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flat Insert
Study: NCT03591718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution for injection
Study: NCT02441023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional therapy and education
Description: 1. Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~2. Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
Study: NCT04262726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMOTION
Description: REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
Study: NCT04540965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telaglenastat
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Histamine-H2 Receptor Antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for famotidine
Description: Placebo for Histamine-H2 Receptor Antagonist
Study: NCT01569841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin) once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT02028442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enadenotucirev
Description: Oncolytic virus
Study: NCT01082692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
Study: NCT04188938

Intervention type: OTHER
Intervention: Evaluation of occult pneumothorax in who had a blunt or penetrating chest trauma
Study: NCT01416402

Intervention type: DRUG
Group type: OTHER
Intervention: Arhalofenate
Description: 400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Febuxostat
Description: 80 mg once daily orally for 5 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine
Description: Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
Study: NCT02418039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal protein
Description: A normal protein diet will be administrated in patients with MHE.
Study: NCT02828475

Intervention type: OTHER
Intervention: CALYPSO
Description: Software platform of machine-learning based predictive models of surgical complication.

Intervention type: BEHAVIORAL
Intervention: Standard Care
Description: Previous standard of care based on surgeon judgement alone.
Study: NCT01242345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Monitoring of the capnography curve for early detection of apnea
Study: NCT00559871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fipamezole
Description: Fipamezole in Zydis formulation three times per day for up to 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fipamezole
Description: Fipamezole in Zydis formulation three times per day for up to 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fipamezole
Description: Fipamezole in Zydis formulation three times per day for up to 28 days
Study: NCT02828475

Intervention type: BEHAVIORAL
Intervention: Standard Care
Description: Previous standard of care based on surgeon judgement alone.
Study: NCT04521322

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iota-Carrageenan
Description: Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
Study: NCT00559871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fipamezole
Description: Fipamezole in Zydis formulation three times per day for up to 28 days
Study: NCT01448993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Taking 250mg azithromycin 3 times per week in alternate days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03567850

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem solving Skills Training
Description: Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving Skills Training
Description: Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier.
Study: NCT01657110

Intervention type: OTHER
Group type: OTHER
Intervention: Tea tree oil
Description: Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
Study: NCT01746758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS text messaging referral
Description: The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
Study: NCT01127503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrosine
Description: Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were identically matched to Metyrosine.
Study: NCT00219674

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group I: Video training
Description: Participants will receive the AED with a video that provides instructional training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group II: Video training + enhanced self-efficacy (SE)
Description: Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group III: In-person training + enhanced SE
Description: Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group IV: In-person training + enhanced SE + support
Description: Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
Study: NCT01236716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine plus carboplatin
Description: Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
Study: NCT03176927

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetogastrogram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetogastrogram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetogastrogram
Study: NCT04521322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iota-Carrageenan
Description: Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
Study: NCT04143867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nolix Device
Description: For temporary management of SUI
Study: NCT04101266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: 30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular and infraclavicular nerve block
Description: 30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
Study: NCT03199378

Intervention type: OTHER
Intervention: Neuropsychological Testing
Description: Each group will be administered a battery of neuropsychological tests

Intervention type: OTHER
Intervention: Neuropsychological Testing
Description: Each group will be administered a battery of neuropsychological tests

Intervention type: OTHER
Intervention: Neuropsychological Testing
Description: Each group will be administered a battery of neuropsychological tests
Study: NCT02332551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Description: Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
Study: NCT01263288

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
Study: NCT03707769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPS microspheres
Description: TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
Study: NCT03298828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR and PD-1 knock out engineered T-cells
Description: A single dose of 1 x 10\^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cells
Description: A single dose of 1 x 10\^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
Study: NCT04334304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Prosthesis - type Bicruciate retaining
Description: A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
Study: NCT00993525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab
Description: 0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
Study: NCT03899220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Matter
Description: This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Matter
Description: This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
Study: NCT03070353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextran 40
Description: Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
Study: NCT01470846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural analgesia
Description: thoracic position (T8-T9 or T11-T12) depending on the site of surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
Study: NCT00202904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
Study: NCT02223767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Verum TMS
Description: Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Sham TMS
Description: Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
Study: NCT00853177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEOPA inhalation
Description: N2O of 50% and 50% O2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xylocaine
Description: Ampoule-bottle of 20 ml
Study: NCT04197570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthetics
Description: see arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non Opioid Analgesics
Description: see arm/group description